Deciphera Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Deciphera Pharmaceuticals is Steve Hoerter, benoemd in Mar2019, heeft een ambtstermijn van 5.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.01M, bestaande uit 12.3% salaris en 87.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.084% van de aandelen van het bedrijf, ter waarde $ 1.86M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 9 jaar.

Belangrijke informatie

Steve Hoerter

Algemeen directeur

US$6.0m

Totale compensatie

Percentage CEO-salaris	12.3%
Dienstverband CEO	5.3yrs
Eigendom CEO	0.08%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	9yrs

Recente managementupdates

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10

Analyse CEO-vergoeding

Hoe is Steve Hoerter's beloning veranderd ten opzichte van Deciphera Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$190m
Dec 31 2023	US$6m	US$738k	-US$195m
Sep 30 2023	n/a	n/a	-US$194m
Jun 30 2023	n/a	n/a	-US$187m
Mar 31 2023	n/a	n/a	-US$182m
Dec 31 2022	US$4m	US$703k	-US$179m
Sep 30 2022	n/a	n/a	-US$221m
Jun 30 2022	n/a	n/a	-US$258m
Mar 31 2022	n/a	n/a	-US$286m
Dec 31 2021	US$9m	US$676k	-US$300m
Sep 30 2021	n/a	n/a	-US$274m
Jun 30 2021	n/a	n/a	-US$258m
Mar 31 2021	n/a	n/a	-US$255m
Dec 31 2020	US$8m	US$650k	-US$266m
Sep 30 2020	n/a	n/a	-US$271m
Jun 30 2020	n/a	n/a	-US$263m
Mar 31 2020	n/a	n/a	-US$218m
Dec 31 2019	US$9m	US$435k	-US$192m
Sep 30 2019	n/a	n/a	-US$157m
Jun 30 2019	n/a	n/a	-US$126m
Mar 31 2019	n/a	n/a	-US$126m
Dec 31 2018	US$447k	n/a	-US$100m

Compensatie versus markt: De totale vergoeding ($USD 6.01M ) Steve } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.64M ).

Compensatie versus inkomsten: De vergoeding van Steve is gestegen terwijl het bedrijf verliesgevend is.

CEO

Steve Hoerter (53 yo)

5.3yrs

Tenure

US$6,010,712

Compensatie

Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Hoerter	President	5.3yrs	US$6.01m	0.084% $ 1.9m
Thomas Kelly	Executive VP	9.3yrs	US$2.03m	0.049% $ 1.1m
Dashyant Dhanak	Executive VP & Chief Scientific Officer	less than a year	US$3.06m	0% $ 0
Daniel Martin	Senior VP & Chief Commercial Officer	5.8yrs	US$1.58m	0.036% $ 801.7k
Matthew Sherman	Executive VP & Chief Medical Officer	4.7yrs	US$2.13m	0.084% $ 1.8m
Kevin Brodbeck	Senior VP & Chief Technical Officer	less than a year	geen gegevens	geen gegevens
Jennifer Larson	Senior Vice President of Finance & Investor Relations	no data	geen gegevens	geen gegevens
Jeffrey Held	Senior VP & General Counsel	5.3yrs	geen gegevens	geen gegevens
Lisa Price	Senior VP & Chief Human Resources Officer	2.4yrs	geen gegevens	geen gegevens
Jama Pitman	Senior VP & Chief Development Officer	4.3yrs	geen gegevens	0.040% $ 876.3k
Margarida Duarte	Senior VP & Head of International	3.3yrs	geen gegevens	geen gegevens
Rodrigo Soto	Senior Vice President of Clinical Development	3.4yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DCPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Hoerter	President	6.1yrs	US$6.01m	0.084% $ 1.9m
John Martin	Independent Director	9.3yrs	US$388.59k	0% $ 0
Edward Benz	Independent Director	7.7yrs	US$396.09k	0% $ 0
Patricia L. Allen	Independent Director	7.8yrs	US$398.55k	0% $ 0
Ron Squarer	Independent Chairman	4.5yrs	US$403.30k	0% $ 0
Jean-Yves Blay	Member of Scientific Advisory Board	9yrs	geen gegevens	geen gegevens
James Bristol	Independent Director	16.8yrs	US$414.77k	0% $ 0
John Condeelis	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Filip Janku	Member of Scientific Advisory Board	9yrs	geen gegevens	geen gegevens
F. Hodi	Member of Scientific Advisory Board	9yrs	geen gegevens	geen gegevens
Dennis Walsh	Independent Director	9.3yrs	US$386.05k	0.013% $ 281.5k
John de Groot	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

9.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DCPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).

Deciphera Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

President recently sold US$471k worth of stock

Senior VP & Chief Commercial Officer recently sold US$224k worth of stock

President recently sold US$259k worth of stock

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Independent Director recently bought US$152k worth of stock

Recent updates

Deciphera Pharmaceuticals, Inc. Files Form 15

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index

Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet

First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Price target increased by 7.1% to US$25.38

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Diving Into Deciphera Pharmaceuticals

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus estimates of losses per share improve by 12%

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

President recently sold US$471k worth of stock

Senior VP & Chief Commercial Officer recently sold US$224k worth of stock

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President recently sold US$259k worth of stock

Price target increased by 11% to US$24.44

Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting

Independent Director recently bought US$152k worth of stock

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

First quarter 2023 earnings: EPS and revenues miss analyst expectations

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Executive VP recently sold US$51k worth of stock

Now 20% undervalued

Price target increased to US$21.10

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$20.25

Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Insufficient new directors

Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting

Insufficient new directors

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022

Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Price target decreased to US$59.27